Skip to main content

Advertisement

Table 2 Summary of changes in MSTCQ scores from Week 4 to 12 in the intent-to-treat population (n = 119)

From: Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

Time point ISR* FLS* GSE
Week 4 (n = 115)    
   Mean (SD) 13.2 (4.02) 13.4 (4.56) 6.8 (3.16)
   Median (range) 13 (4-19) 13 (6-20) 6 (3-15)
Week 8 (n = 109)    
   Mean (SD) 13.4 (3.64) 12.9 (4.10) 7.5 (3.16)
   Median (range) 13.5 (6-20) 12 (5-20) 8 (3-15)
Week 12 (n = 104)    
   Mean (SD) 13.1 (3.39) 12.2 (4.30) 7.6 (3.05)
   Median (range) 13 (6-20) 11 (5-20) 8 (3-15)
p-value 0.902 0.022 0.002
  1. *Range: 1 (mild) to 20 (severe)
  2. Range: 1 (poor treatment satisfaction) to 15 (excellent treatment satisfaction)
  3. Repeated measures analysis of variance
  4. FLS 'flu-like' symptoms, GSE global side effects, ISR injection-site reactions; MSTCQ Multiple Sclerosis Treatment Concern Questionnaire, SD standard deviation